LY4584180 + Rituximab
Phase 1Recruiting 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Non-Hodgkin's
Conditions
Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
Trial Timeline
Feb 1, 2026 → Dec 1, 2029
NCT ID
NCT07226843About LY4584180 + Rituximab
LY4584180 + Rituximab is a phase 1 stage product being developed by Eli Lilly for Lymphoma, Non-Hodgkin's. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07226843. Target conditions include Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma, Non-Hodgkin's were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07226843 | Phase 1 | Recruiting |
Competing Products
20 competing products in Lymphoma, Non-Hodgkin's